“Global Genomics market set to grow to $23bn by 2022” says new Visiongain report

01 November 2018
Pharma

Visiongain has launched a new pharma report: Global Genomics Market Report 2018-2028: Sequencing, Microarray, PCR, Nucleic Acid Extraction and Purification, Diagnostic Test, Genetic Test, Newborn Screening, Preimplantation Testing, Prenatal Testing, Carrier Testing, Molecular Test, Chromosomal Test, Biochemical Test, Diagnostic, Drug Discovery, Precision Medicine, Research Centers, Hospitals and Clinics, Pharmaceutical Companies and Others.

Genome-based research is already empowering medical researchers to develop improved diagnostics, more effective therapeutic strategies, evidence-based approaches for demonstrating clinical efficacy, and better decision-making tools for patients and providers. The genomics market has been segmented based on technology, test type, method, application, end-user, and geography.

The lead analyst of the report commented "Genomics market is quite fragmented. Companies are investing in research and development activities and the industry growth is highly positive. There is a strong and established customer base for genomics market which is continually progressing. The products are very much undifferentiated as the technological arena is limited to certain extents and, each application segment is demanding technological advancement.

With increasing demand for diagnostic and precision medicines, market players are introducing product developments to differentiate themselves with the best and cost-effective solutions to the market. There is a presence of many domestic and global level players with intense competition among each other."

Leading companies featured in the report include Agilent Technologies, Inc., Danaher Corporation, Eppendorf AG, BGI Genomics Co. Ltd., Eurofins Scientific, GE Healthcare Life Sciences, Illumina, Inc., Oxford Nanopore Technologies Ltd., Qiagen NV, Roche, Thermo Fisher Scientific, Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Human Microbiome Therapeutics market set to grow to $1.6bn” by 2025 says new Visiongain report

The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders.

04 December 2019

Read

“Global Next-Generation Biologics market set to grow to $42bn by 2024” says new Visiongain report

Technological developments in the next-generation biologics market will be the result of clinical development of multiple platforms in the next-generation antibody, antibody fragment and ALP sectors.

04 December 2019

Read

“Global Liquid Biopsy market set to grow to $4.9bn by 2024” says new Visiongain report

The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

04 December 2019

Read

“Global nucleic acid isolation and purification market is anticipated to reach USD 8.16 Billion by 2030”, says Visiongain

Nucleic acid separation and purification is one of modern science and technology’s most complex and critical accomplishments.

29 November 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever